Cassava flunks phase 3 Alzheimer’s test, triggering early end of second trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing secondary and exploratory biomarker endpoints, the biotech has pulled the plug on another phase 3 trial and an open-label extension.
Modeled after the state’s $6B cancer research fund, the dementia fund could pump hundreds of millions of dollars into Texas ...
Alzheimer’s disease affects more than 50 million people worldwide, often devastating both the individuals who have it and ...
Dear Quentin, I have two sisters who have developed Alzheimer’s disease. My younger sister is actually more severely ...
Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...
Nov. 21—John Haldi had early-stage Alzheimer's disease when he began a local Aduhelm drug study in June 2020. For three ...
People with Alzheimer's exhibit a loss of motor control along with cognitive decline, and one of the earliest signs of this decay can be spotted in involuntary eye movements known as saccades. These ...
Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...
Cassava Sciences Inc.’s stock SAVA was halted after falling 5% in premarket trade Monday, after the company said a trial of a treatment for mild-to-moderate Alzheimer’s disease failed to meet its ...
The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest with recent years ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback